Navigation Links
New Report Tackles the Changing Landscape for Alzheimer's Diagnostics and Treatments
Date:1/28/2008

SCOTTSDALE, Ariz., Jan. 28 /PRNewswire/ -- MedPredict has published "Thought Leader Insight & Analysis: Alzheimer's Disease," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area.

"Given the size of this patient population and the lack of approved therapeutics for long-term disease control, it is not surprising to see the large number of companies racing to bring Alzheimer's drugs to market," notes MedPredict president Jeff Berk. "Our panel of experts attempts to sort through the hype, and identify the approaches with the most promising early data." Dr. Berk conducted in-depth interviews with a panel of leading experts in Alzheimer's disease as the basis for this report.

In this report, the panel reviews major developments this past year and forecasts the changes they expect to see in the Alzheimer's competitive landscape in 2008. Each panelist offers his perspective on those agents and mechanisms that have the strongest data supporting them, and comments on those where the excitement extends beyond the clinical evidence. These include acetylcholinesterase (butyrylcholinesterase) inhibitors, NMDA, M1, 5-HT, alpha-7 nicotinic acetylcholine agonists, active and passive immunotherapy, gamma-secretase and beta-secretase inhibitors, insulin related mechanisms (IDE, RAGE), plasminogen activator inhibitor-1, anti-TNF, GSK3 and more.

In addition to the drugs highlighted as most interesting by the experts, this report offers a "program guide" of new compounds, reflecting the many and varied mechanisms being pursued to approach diagnosis and treatment of this disease.

Companies/Partnerships discussed in this report: General Electric, Bateman/Holtzman, Bayer-Schering/Avid Radiopharmaceuticals, Satoris, Neurochem, Sanofi-Aventis, Eisai/Pfizer, Novartis, J&J, Debio, TorreyPines, Forest/Merz/Lundbeck/Daiichi-Sankyo, Medivation, Merck, GSK, Neuropharma/Zeltia, Abbott, AstraZeneca, Roche/Memory, EnVivo/Bayer-Schering, Baxter, Elan/Wyeth, Lilly, Pfizer, Eisai/BioArctic, Roche/Morphosys, AC Immune/Genentech, Affiris, AC Immune, Boehringer-Ingelheim/Ablynx, Lundbeck/Pharmexa, Myriad, Lilly/Elan, Wyeth , Schering-Plough, Elan, BMS, TorreyPines, Cellzome/J&J, CoMentis, Sunesis/Merck, Astex/AstraZeneca, Amgen, Wyeth/Amgen, TransTec/Pfizer, Accera, Sirtris, Neuropharma, Prana, Epix/GSK, Elan/Transition Therapeutics

The full report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The Dark Report and Siemens Introduce the Worlds First Integrated Molecular Summit
2. Varian, Inc. Reports First Quarter 2008 Results
3. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
4. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
5. VNUS Medical Technologies to Report Fourth-Quarter 2007 Results and Webcast Teleconference on February 7
6. Quest Diagnostics Sets New Date to Report Fourth Quarter and Full Year 2007 Results
7. Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues
8. Pharmasset Reports Fiscal Year End 2007 Financial Results
9. Avitar Reports Fourth Quarter and Fiscal Year 2007 Financial Results
10. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
11. Imagenetix Reports Results of Offer to Extend Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Spain , Dec. 8, 2016  Anaconda BioMed ... the development of the next generation neuro-thrombectomy system for ... appointment of Tudor G. Jovin, MD to join its ... serve as a strategic network of scientific and clinical ... the development of the ANCD BRAIN ® to ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... launch of flexible packaging for their exceptionally efficient human mesenchymal stem/stromal cell ... RoosterBio’s portfolio of bioprocess media products engineered to radically streamline culture processes, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... This CAST literature ... for biotech crops. The authors focus on the economic effects in countries that are ... of new biotech crops and the resultant risk of low level presence (LLP) puts ...
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. ... company focused on developing and commercializing products to treat ... announced today that it will be hosting an Investor ... ET on the origins of innate defense regulators (IDRs) ... review of oral mucositis and the recently announced and ...
Breaking Biology Technology:
(Date:11/17/2016)... CITY OF INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it ... about using NVMe storage servers in organizations that require high-performance scale-out plus high speed data transfer ... ... ... Setting ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:11/14/2016)... SARASOTA, Fla., Nov. 14, 2016  xG Technology, Inc. ... in providing critical wireless communications for use in challenging ... ended September 30, 2016. Management will hold a conference ... at 5:00 p.m. Eastern Time (details below). ... announced a $16 million binding agreement to acquire Vislink ...
Breaking Biology News(10 mins):